Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142


Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.

Tseng D, Rachakonda LP, Su Z, Advani R, Horning S, Hoppe RT, Quon A, Graves EE, Loo BW Jr, Tran PT.

Radiat Oncol. 2012 Jan 19;7:5. doi: 10.1186/1748-717X-7-5.


Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.

Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, Yu J.

Lung Cancer. 2011 Sep;73(3):332-7. doi: 10.1016/j.lungcan.2011.01.007.


Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.

Lee H, Kim SK, Kim YI, Kim TS, Kang SH, Park WS, Yun T, Eom HS.

J Nucl Med. 2014 Feb;55(2):216-22. doi: 10.2967/jnumed.113.124172.


Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.

Song MK, Chung JS, Lee JJ, Jeong SY, Lee SM, Hong JS, Chong A, Moon JH, Kim JH, Lee SM, Kim SJ, Shin HJ.

Cancer Sci. 2013 Dec;104(12):1656-61. doi: 10.1111/cas.12282.


18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.

Kahraman D, Theurich S, Rothe A, Kuhnert G, Sasse S, Scheid C, Dietlein M, Drzezga A, von Bergwelt-Baildon M, Kobe C.

Leuk Lymphoma. 2014 Apr;55(4):811-6. doi: 10.3109/10428194.2013.819575.


Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.

Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002.


Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.

Khong PL, Huang B, Lee EY, Chan WK, Kwong YL.

J Nucl Med. 2014 Jun;55(6):911-6. doi: 10.2967/jnumed.113.131946.


Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.

Ryu IS, Kim JS, Roh JL, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY.

J Nucl Med. 2013 Jul;54(7):1032-8. doi: 10.2967/jnumed.112.116053.


Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.

Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, Loo BW Jr, Koong AC, Chang DT.

Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):471-7. doi: 10.1016/j.ijrobp.2011.12.029.


The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.

Schrepfer T, Haerle SK, Strobel K, Schaefer N, Hälg RA, Huber GF.

Laryngoscope. 2010 May;120(5):937-44. doi: 10.1002/lary.20843.


Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma.

Bai B, Huang HQ, Cai QC, Fan W, Wang XX, Zhang X, Lin ZX, Gao Y, Xia YF, Guo Y, Cai QQ, Jiang WQ, Lin TY.

Med Oncol. 2013 Mar;30(1):339. doi: 10.1007/s12032-012-0339-0.


Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.

Chen HH, Chiu NT, Su WC, Guo HR, Lee BF.

Radiology. 2012 Aug;264(2):559-66. doi: 10.1148/radiol.12111148.


Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A.

J Clin Oncol. 2007 Aug 20;25(24):3746-52.


Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38. doi: 10.1007/s00259-011-1934-6.


Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.

Ferrari C, Niccoli Asabella A, Merenda N, Altini C, Fanelli M, Muggeo P, De Leonardis F, Perillo T, Santoro N, Rubini G.

Medicine (Baltimore). 2017 Feb;96(5):e5973. doi: 10.1097/MD.0000000000005973.


Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.

Simontacchi G, Filippi AR, Ciammella P, Buglione M, Saieva C, Magrini SM, Livi L, Iotti C, Botto B, Vaggelli L, Re A, Merli F, Ricardi U.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1077-83. doi: 10.1016/j.ijrobp.2015.04.021.


Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes.

Chu KP, Murphy JD, La TH, Krakow TE, Iagaru A, Graves EE, Hsu A, Maxim PG, Loo B, Chang DT, Le QT.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1521-7. doi: 10.1016/j.ijrobp.2011.10.022.


Quantitative analysis of basal and interim PET/CT images for predicting tumor recurrence in patients with Hodgkin's lymphoma.

Strigari L, Attili A, Duggento A, Chiaravalloti A, Schillaci O, Guerrisi MG.

Nucl Med Commun. 2016 Jan;37(1):16-22. doi: 10.1097/MNM.0000000000000399.

Items per page

Supplemental Content

Support Center